Greg Friberg

697 total citations
15 papers, 488 citations indexed

About

Greg Friberg is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Greg Friberg has authored 15 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Greg Friberg's work include Cancer, Hypoxia, and Metabolism (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cancer Treatment and Pharmacology (3 papers). Greg Friberg is often cited by papers focused on Cancer, Hypoxia, and Metabolism (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cancer Treatment and Pharmacology (3 papers). Greg Friberg collaborates with scholars based in United States. Greg Friberg's co-authors include Hongjie Deng, Ian McCaffery, Bruce J. Roth, Barbara A. Murphy, Anthony W. Tolcher, Jordi Rodón, Amita Patnaik, Brianne Kaiser, Kyriakos P. Papadopoulos and Chia‐Chi Lin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Greg Friberg

15 papers receiving 475 citations

Peers

Greg Friberg

ONCOL

PRM

EDM

Brianne Kaiser United States

Heather M. Shaw United Kingdom

Daniela Morales-Espinosa Spain

Ann W. Gramza United States

Sylwia Szpak‐Ulczok Poland

Juergen Mestan Switzerland

Ashraf S. Mahmoud-Ahmed United States

Masako Uno Japan

P. Dieringer United States

Hidenori Mizugaki Japan

Brianne Kaiser United States

Greg Friberg

405 ×1.6

227 ×1.2

ONCOL

132 ×1.1

PRM

96 ×0.9

EDM

97 ×1.0

Citations per year, relative to Greg Friberg Greg Friberg (= 1×) peers Brianne Kaiser

Countries citing papers authored by Greg Friberg

Since Specialization

Citations

This map shows the geographic impact of Greg Friberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Friberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Friberg more than expected).

Fields of papers citing papers by Greg Friberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Friberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Friberg. The network helps show where Greg Friberg may publish in the future.

Co-authorship network of co-authors of Greg Friberg

This figure shows the co-authorship network connecting the top 25 collaborators of Greg Friberg. A scholar is included among the top collaborators of Greg Friberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg Friberg. Greg Friberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Friberg, Greg & David Reese. (2017). Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL). Annals of Oncology. 28(8). 2009–2012. 21 indexed citations

Wu, Benjamin, et al.. (2017). A Pharmacokinetic and Safety Study of Trebananib, an Fc‐Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction. Clinical Pharmacology & Therapeutics. 102(2). 313–320. 4 indexed citations

Fleming, Gini F., et al.. (2015). Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 15(1). 69–69. 20 indexed citations

Diamond, Jennifer R., Benjamin Wu, Neeraj Agarwal, et al.. (2015). Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Investigational New Drugs. 33(3). 691–699. 6 indexed citations

Schuster, Michael W., Mikkael A. Sekeres, Érick Gamelin, et al.. (2015). Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients (Pts) with Acute Myeloid Leukemia (AML). Blood. 126(23). 4929–4929. 2 indexed citations

Juan, Gloria, Tammy L. Bush, Raffi Manoukian, et al.. (2014). AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues. Journal of Translational Medicine. 12(1). 307–307. 10 indexed citations

Hong, David S., Razelle Kurzrock, Marilyn Mulay, et al.. (2014). A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget. 5(22). 11154–11167. 12 indexed citations

Rossin, Raffaella, Tadahiko Kohno, Aviv Hagooly, et al.. (2011). Characterization of ⁶⁴Cu-DOTA-Conatumumab: A PET Tracer for In Vivo Imaging of Death Receptor 5. Journal of Nuclear Medicine. 52(6). 942–949. 12 indexed citations

Herbst, Roy S., Razelle Kurzrock, David S. Hong, et al.. (2010). A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 16(23). 5883–5891. 111 indexed citations

10.

Puzanov, Igor, John Sarantopoulos, Jeremy L. Gilbert, et al.. (2010). Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3018–3018. 4 indexed citations

11.

Zoog, Stephen J., Paula Kaplan‐Lefko, Jodi Moriguchi, et al.. (2010). Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling. Cytometry Part A. 77A(9). 849–860. 14 indexed citations

12.

Tap, William D., G. D. Demetri, Phillip Barnette, et al.. (2010). AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results.. Journal of Clinical Oncology. 28(15_suppl). 10001–10001. 18 indexed citations

13.

Tolcher, Anthony W., John Sarantopoulos, Amita Patnaik, et al.. (2009). Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1. Journal of Clinical Oncology. 27(34). 5800–5807. 237 indexed citations

14.

Kindler, Hedy L., Kathryn Bylow, H. S. Hochster, et al.. (2006). A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis. Journal of Clinical Oncology. 24(18_suppl). 4040–4040. 15 indexed citations

15.

Friberg, Greg, L. Philip Schumm, Mark J. Ratain, Richard L. Schilsky, & Gini F. Fleming. (2004). Circadian variations in plasma 5-fluorouracil (5-FU) levels during 24-hour infusions. Journal of Clinical Oncology. 22(14_suppl). 2055–2055. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact